about
Gonadotropin releasing hormone analogue (GnRHa) alters the expression and activation of Smad in human endometrial epithelial and stromal cellsTherapeutic strategies for ovulation induction in infertile women with polycystic ovary syndrome.Comparison of gonadotropin-releasing hormone agonist with GnRH antagonist in polycystic ovary syndrome patients undergoing in vitro fertilization cycle: Retrospective analysis from a tertiary center and review of literatureAccumulation of oocytes and/or embryos by vitrification: a new strategy for managing poor responder patients undergoing pre implantation diagnosisGonadotropin-releasing hormone type II antagonist induces apoptosis in MCF-7 and triple-negative MDA-MB-231 human breast cancer cells in vitro and in vivo.Is a GnRH antagonist protocol better in PCOS patients? A meta-analysis of RCTs.Safety of GnRH agonists and antagonists.Effect of GnRH antagonists on clinical pregnancy rates in ovulation induction protocols with gonadotropins and intrauterine inseminationA Flexible Multidose GnRH Antagonist versus a Microdose Flare-Up GnRH Agonist Combined with a Flexible Multidose GnRH Antagonist Protocol in Poor Responders to IVF.A Patient Friendly Corifollitropin Alfa Protocol without Routine Pituitary Suppression in Normal Responders.Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome?Luteal phase oestradiol administration in ovarian stimulation cycles with GnRH antagonist is comparable to the GnRH agonist (long) protocolThe effects of GnRH antagonist on the endometrium of normally menstruating women.Use of oral contraceptives in infertile patients: A descriptive review.GnRH antagonists may affect endometrial receptivity.Gonadotrophin releasing hormone antagonist in IVF/ICSI.Impact of gonadotropin-releasing hormone antagonist addition on pregnancy rates in gonadotropin-stimulated intrauterine insemination cyclesObservational Study to Assess the Therapeutic Value of Four Ovarian Hyperstimulation Protocols in IVF After Pituitary Suppression with GnRH Antagonists in Normally Responding Women.GnRH antagonist, cetrorelix, for pituitary suppression in modern, patient-friendly assisted reproductive technology.Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART).Luteinizing hormone-releasing hormone antagonists.Gonadotropin-releasing hormone and TGF-beta activate MAP kinase and differentially regulate fibronectin expression in endometrial epithelial and stromal cells.Effects of luteal estradiol pre-treatment on the outcome of IVF in poor ovarian responders.Could the addition of hp-hMG and GnRH antagonists modulate the response in IVF-ICSI cycles?Subtle progesterone rise in the single-dose gonadotropin-releasing hormone antagonist (cetrorelix) stimulation protocol in patients undergoing in vitro fertilization or intracytoplasmic sperm injection cycles.Transport IVF-ICSI: Results of a 25-year experience.Comparison of modified agonist, mild-stimulation and antagonist protocols for in vitro fertilization in patients with diminished ovarian reserve.
P2860
Q24806736-3B67624D-A7E8-44E1-8FCD-554DAABEE152Q33230782-845A5A35-9D2D-4795-93F1-883987D4D16DQ33601506-94D7D1CB-2433-4505-9146-6423A6841E83Q33950722-86C46C3A-6578-4207-B1AE-765AEF6EB657Q34173433-072BDB5E-929E-4952-8D05-A187C55EFE8AQ35123968-14A619B2-41F0-4D56-A2BD-FF8DCAEF7B72Q35609748-4C88603C-99C3-4406-8559-1886C9653B21Q35749543-8BBF5708-2CD4-46EA-A25D-99F6E4DA0D7BQ35804563-FF884DEA-92FE-4E41-9433-AD553623BEE5Q35995836-A97FB2DE-8A92-4AD4-8411-DE11506D1717Q36001614-4C7046C6-156F-4FB8-98DB-DDD9F383258CQ36268361-3E0C5C25-DCDB-47CA-8126-3DBFE5FF5C2DQ36268633-409756ED-661F-4111-9D8E-625DE02D2283Q36668521-0AC7CABA-3157-400B-A916-F6969BC93ABBQ37235118-F65A9E31-DCC8-4F66-B510-C2DD7B598714Q37238190-3DF88989-19A8-466A-A4A9-12B8BF69E159Q37350469-75740550-5319-4F09-B0E2-A320A6EC25E6Q37463040-6F014302-367A-4658-80D2-B8856E026BA5Q37598922-065ECB74-3D10-4AC6-A476-8C4B43205A8DQ37606149-08108E03-E154-4F6F-8A50-6D5E9A80B724Q37638747-143E3595-9F01-49B4-83AA-4AD2D8EF1934Q40533221-862F5D46-5ED1-48BE-B869-DDA75860E930Q48635309-21E4B2AC-F5AF-463F-83B4-9BB556ABFEEEQ48701805-560D9AF3-4DE4-42EF-BB17-A2E1864E8BFFQ48787898-A01EC8FC-2834-4944-A6CB-37A255779232Q55082016-8F4EBFA2-E552-4929-A678-6C9F46DDFA86Q55449124-CEDC201D-8AC8-49F4-A943-1F5D789D5D17
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The use of GnRH antagonists in ovarian stimulation.
@ast
The use of GnRH antagonists in ovarian stimulation.
@en
The use of GnRH antagonists in ovarian stimulation.
@nl
type
label
The use of GnRH antagonists in ovarian stimulation.
@ast
The use of GnRH antagonists in ovarian stimulation.
@en
The use of GnRH antagonists in ovarian stimulation.
@nl
prefLabel
The use of GnRH antagonists in ovarian stimulation.
@ast
The use of GnRH antagonists in ovarian stimulation.
@en
The use of GnRH antagonists in ovarian stimulation.
@nl
P2093
P356
P1476
The use of GnRH antagonists in ovarian stimulation
@en
P2093
F Olivennes
P Bouchard
P304
P356
10.1093/HUMUPD/8.3.279
P577
2002-05-01T00:00:00Z